Long Term Evaluations of First Single-dose Rituximab in Children with Steroid-Dependent Minimal-Change Nephrotic Syndrome

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2024 Nov 27

PMID 39593209

Authors

Xiao-Ling Niu

Yun-Fan Gu

Dan Feng

Sheng Hao

Xin-Yu Kuang

Ping Wang

Wen-Yan Huang

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the long-term efficacy and safety of the first single dose of rituximab in children with steroid-dependent minimal-change nephrotic syndrome (SD-MCNS) over a two-year period after infusion.

Methods: A 2-year retrospective observational study was performed on children with SD-MCNS who received the first single dose of rituximab (375 mg/m) from October 2011 to December 2018.

Results: Seventy-seven patients (median age 8.17 years) were included. The efficacy of the first single-dose rituximab in children with SD-MCNS was 90.91% (70/77). An overall relapse rate of 78.33% was achieved. Older age at rituximab treatment onset (>8.46 years), a lower steroid-dependent dosage (<18.76 mg/m·d) and a higher CD4 T-cell count before rituximab treatment (>31.22%) were positively related to treatment efficacy (0.05). Male sex, younger age at rituximab treatment onset, a higher IgE level before rituximab treatment, and a higher white blood cell count and CD3 T-cell count at the time of steroid withdrawal were associated with disease relapse (0.05). A model for predicting relapse after rituximab treatment in SD-MCNS patients was established.

Conclusions: The first single-dose rituximab treatment for children with SD-MCNS was effective and safe. Greater efficacy was observed in patients who were older at rituximab treatment onset, had a lower steroid-dependent dosage, or had a higher CD4 T-cell count before rituximab treatment. In contrast, younger male patients with a higher IgE level experienced an increased occurrence of relapse.

References

Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y . Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010; 25(3):539-44. DOI: 10.1007/s00467-009-1377-5. View

Ravani P, Lugani F, Drovandi S, Caridi G, Angeletti A, Ghiggeri G . Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults: A Randomized Clinical Trial. JAMA Pediatr. 2021; 175(6):631-632. PMC: 7900932. DOI: 10.1001/jamapediatrics.2020.6150. View

Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra T . Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. JAMA Pediatr. 2018; 172(8):757-764. PMC: 6142920. DOI: 10.1001/jamapediatrics.2018.1323. View

Niu X, Hao S, Wang P, Zhang W, Guo G, Wu Y . Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome. Biomed Rep. 2016; 5(2):237-242. PMC: 4950748. DOI: 10.3892/br.2016.711. View

Basu B, Preussler S, Sander A, Mahapatra T, Schaefer F . Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome. BMC Nephrol. 2020; 21(1):520. PMC: 7706288. DOI: 10.1186/s12882-020-02153-5. View

Maxted A, Dalrymple R, Chisholm D, McColl J, Tse Y, Christian M . Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatr Nephrol. 2018; 34(5):855-863. PMC: 6424916. DOI: 10.1007/s00467-018-4172-3. View

Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang S, Henique C . NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome. J Autoimmun. 2017; 88:91-102. DOI: 10.1016/j.jaut.2017.10.006. View

Kamei K, Ogura M, Sato M, Ito S, Ishikura K . Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. Pediatr Nephrol. 2018; 33(6):1013-1018. DOI: 10.1007/s00467-018-3900-z. View

Zurowska A, Drozynska-Duklas M, Topaloglu R, Bouts A, Boyer O, Shenoy M . Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatr Nephrol. 2023; 38(9):3035-3042. PMC: 10432325. DOI: 10.1007/s00467-023-05913-1. View

10.

Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T . Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome. J Am Soc Nephrol. 2021; 33(2):401-419. PMC: 8819987. DOI: 10.1681/ASN.2021050643. View

11.

Girisgen I, Yuksel S, Pekal Y . Rituximab experience in children with nephrotic syndrome: what have we observed differently. Turk Pediatri Ars. 2020; 55(1):60-66. PMC: 7096562. DOI: 10.14744/TurkPediatriArs.2019.76148. View

12.

Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S . Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol. 2016; 21(4):671-676. DOI: 10.1007/s10157-016-1328-y. View

13.

Kari J, Alhasan K, Albanna A, Safdar O, Shalaby M, Bockenhauer D . Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2020; 35(8):1445-1453. DOI: 10.1007/s00467-020-04570-y. View

14.

Jacobs R, Langer-Jacobus T, Duong M, Stahl K, Haller H, Schmidt R . Detection and quantification of rituximab in the human urine. J Immunol Methods. 2017; 451:118-121. DOI: 10.1016/j.jim.2017.09.001. View

15.

Chan E, Tullus K . Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen. Pediatr Nephrol. 2020; 36(6):1397-1405. DOI: 10.1007/s00467-020-04609-0. View

16.

Iwabuchi Y, Miyabe Y, Makabe S, Nakano M, Manabe S, Karasawa K . Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease. Medicine (Baltimore). 2018; 97(42):e12704. PMC: 6211879. DOI: 10.1097/MD.0000000000012704. View

17.

Kallash M, Smoyer W, Mahan J . Rituximab Use in the Management of Childhood Nephrotic Syndrome. Front Pediatr. 2019; 7:178. PMC: 6524616. DOI: 10.3389/fped.2019.00178. View

18.

Hogan J, Dossier C, Kwon T, Macher M, Maisin A, Couderc A . Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2018; 34(2):253-259. DOI: 10.1007/s00467-018-4052-x. View

19.

Ravani P, Lugani F, Pisani I, Bodria M, Piaggio G, Bartolomeo D . Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatr Nephrol. 2020; 35(8):1437-1444. DOI: 10.1007/s00467-020-04540-4. View

20.

Chan E, Webb H, Yu E, Ghiggeri G, Kemper M, Ma A . Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int. 2019; 97(2):393-401. DOI: 10.1016/j.kint.2019.09.033. View